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htcense.Abstract Background: The most common and most serious complication of varicella (chicken-
pox) in adults is pneumonia, which can lead to severe respiratory failure. Whether addition of cor-
ticosteroids to antiviral treatment beneﬁts patients with varicella pneumonia is unclear.
Objectives: To assess the effect of dexamethasone as adjunctive therapy for treatment of varicella
pneumonia on the length of hospital stay, which might cause earlier resolution of varicella pneumo-
nia.
Patients and methods: Forty patients were diagnosed as varicella pneumonia and divided into
two groups, the ﬁrst one involved 20 patients who received dexamethasone and acyclovir, and
the second one involved also 20 patients but they received placebo and acyclovir. We measured liver
function test, kidney proﬁle, complete blood count, blood glucose, C-reactive protein and the levels
of interleukin-6 on the day of presentation, after 4 days of admission and on the day of discharge
from the hospital.
Result: The mean length of hospital stay in the dexamethasone group was 6.5 days compared
with 7.1 days in the placebo group and was signiﬁcantly different between two groups. The mean
time of switching to oral administration of acyclovir was 3.4 days in the dexamethasone group
and 4.2 days in the placebo group. The mean time of switching to oral was signiﬁcantly lower in
dexamethasone group than in placebo group.
Conclusion: Adding of dexamethasone to acyclovir in patients with varicella pneumonia can
reduce the length of hospital stay.
ª 2012 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
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Varicella (chickenpox) is a common contagious infection
caused by varicella-zoster virus with a benign outcome in chil-
dren. However, pneumonia is the major and most frequent
complication of varicella in healthy adults, with incidencesis. Production and hosting by Elsevier B.V.
.10.019
10 M.A. Saraya, A.E.-A.I. Amalbeing reported as high as 50% [1] and carries an overall
mortality rate of between 10% and 30% [2].
It has been reported that the susceptibility of varicella
pneumonia in healthy adults is 25-fold greater than in children.
Mortality rates approach 50% in patients who experience
respiratory failure which requires mechanical ventilation, de-
spite appropriate supportive and aggressive therapy [2]. Smok-
ing [1] and pregnancy [3] are well-known as risk factors linked
to the development of varicella pneumonia in adults. Patients
with chronic lung disease are also at risk of manifesting vari-
cella pneumonia [2].
Varicella pneumonia typically develops within 1–6 days
after the onset of rash with symptoms of cough, dyspnea, chest
tightness, fever and occasionally with chest pain and hemopt-
ysis. In a limited number of cases, pulmonary symptoms may
be present before the appearance of the skin rash [1]. Patients
demonstrate impaired gas exchange with progressive hypox-
emia. Chest radiographs typically reveal diffuse nodular opac-
ities, progressing to extensive air-space consolidation [4]. The
pulmonary lesions caused by acute varicella infection consist
of endothelial damage in small blood vessels, with focal hem-
orrhagic necrosis, mononuclear inﬁltration of alveolar walls
and ﬁbrinous exudates with macrophages in the alveoli, which
contain eosinophilic intranuclear inclusions [5].
The main stays of treatment for varicella pneumonia are
early diagnosis and initiation of intravenous acyclovir [6].
Adjunctive therapy for varicella pneumonia might help to re-
duce disease severity. Varicella pneumonia causes an intersti-
tial pneumonitis and this pneumonitis is deemed to be due to
the host response rather than to speciﬁc virally mediated tissue
injury [7]. Corticosteroids may potentially modify the inﬂam-
matory response when administered early [8]. Corticosteroids
are very potent inhibitors of inﬂammation [9]. They switch
off genes that encode pro-inﬂammatory cytokines and switch
on genes that encode anti-inﬂammatory cytokines. Treatment
with low dose corticosteroids down regulates pro-inﬂamma-
tory cytokine transcription, which prevents an extended cyto-
kine response and might accelerate the resolution of systemic
and pulmonary inﬂammation in the early phase of varicella
pneumonia [10]. Corticosteroids inhibit also the production
of membrane-derived products such as leukotrienes and pros-
taglandins by inﬂammatory cells, with a consequent decreases
in edema and vascular permeability allowing improvement of
pulmonary gas exchange [11].
We postulated that adjunctive treatment of varicella pneu-
monia with intravenous dexamethasone might change the im-
mune response and thereby reduce morbidity and length of
stay of patient in hospital. Dexamethasone has potent anti-
inﬂammatory effects and weak mineralocorticoid effects com-
pared with other corticosteroid, thus avoiding interference
with sodium re-absorption and water balance. Moreover,
dexamethasone has a long lasting effect, allowing for a once-
a-day regimen [12].Aim of the work
We aimed in this study to assess the effect of intravenous
dexamethasone compared with placebo on length of hospital
stay in non-immunocompromised patients who were admitted
to hospital with chickenpox complicated by varicella
pneumonia.Patients and methods
We undertook 40 patients were diagnosed as varicella pneumo-
nia at Infectious Disease Hospital (IDH) which is the only ter-
tiary infectious hospital in Kuwait. Diagnosis of varicella
pneumonia was based on the presence of a typical rash of chic-
kenpox associated with development of respiratory symptoms
and radiological ﬁndings of diffuse interstitial or nodular inﬁl-
trates within 10 days following the onset of clinically evident
varicella infection.
Serological conﬁrmation was not performed. Hypoxemia
was deﬁned as low level of oxygen in the blood (PaO2ﬁ
80 mmhg). Levels of hypoxemiawere deﬁned asmild hypoxemia
(PaO2ﬁ 60–79 mmhg), moderate hypoxemia (PaO2ﬁ 40–
59mmhg), sever hypoxemia (PaO2ﬁ 40 mmhg) [20].
Patients were excluded if they had a known congenital or
acquired immunodeﬁciency or receipt of chemotherapy, any
dose of corticosteroid, or immunosuppressive medications in
the previous 6 weeks or malignant diseases. Patients who
needed immediate admission to the intensive care unit at pre-
sentation and pregnant or breastfeeding women were also ex-
cluded. Eligible patients who were included in this study
provided written informed consent.
The patients were divided into two groups, the ﬁrst one in-
volved 20 patients who received dexamethasone and acyclovir,
and the second one involved also 20 patients but they received
placebo and acyclovir. All patients were subjected to history
taking and thorough clinical examination. We measured liver
function test (LFT), kidney proﬁle (KP), complete blood count
(CBC), blood glucose, C-reactive protein (CRP) and levels of
the pro-inﬂammatory cytokine interleukin-6 (IL-6) (Biomedix
medical group, Synlab, German) on the day of presentation,
after 4 days of admission and on the day of discharge from
the hospital. We also measured arterial blood gases (ABG)
on the day of presentation and on the day of discharge from
the hospital. Some of the patients in both groups needed O2
therapy in the form of 2–3 L/min of O2 by nasal prongs and
any patients needed mechanical ventilation were excluded
from the study.
Patients in the dexamethasone group were given a bolus of
5 mg (1 ml) of dexamethasone intravenously and the patients
in the placebo group were given 1 ml of sterile water for injec-
tion intravenously once a day at time of admission and for the
subsequent 3 days. All patients received acyclovir intrave-
nously in proper dose according to body weight for 7–10 day
[13].
Statistical analysis
The data was analyzed using the statistical package for social
sciences (spss) version 8.0 software. The signiﬁcance of differ-
ences between mean values of the study variables was evalu-
ated by using t-test. The signiﬁcance of differences between
proportions was performed using the Chi-square test. The P
value less than 0.05 is considered signiﬁcant.
Results
From September, 2010, to November 2011, we enrolled 40 pa-
tients in this study and were divided into two groups, dexa-
methasone group and placebo group; each of them involved
Table 3 Comparison between studied groups at time of discharge.
On discharge
Dexamethasone group Placebo group P-value
ALT 50.35 ± 10.97 51.90 ± 8.86 0.62
AST 40.8 ± 4.47 37.45 ± 6.78 0.07
CRP 5.8 ± 1.5 7.65 ± 1.34 0.000
IL6 5.46 ± 1.02 6.34 ± 1.24 0.019
O2 saturation on room air 98.35 ± 0.87 98.3 ± 0.97 0.86
Po2 on room air 88.5 ± 0.88 88.65 ± 0.86 0.93
PH 7.41 ± 0.032 7.42 ± 0.025 0.15
Length of stay 6.5 ± 0.76 7.15 ± 0.98 0.02
Platelet 191.85 ± 17.55 188.0 ± 20.56 0.52
WBCs 8.54 ± 1.78 8.51 ± 1.84 0.95
Serum creatinine 84.3 ± 11.4 85.8 ± 11.78 0.68
Table 2 Comparison between studied groups after 4 days from admission.
After 4 days from admission
Dexamethasone group Placebo group P-value
ALT 91.13 ± 19.4 109.11 ± 16.2 0.006
AST 71.2 ± 10.3 81.8 ± 7.3 0.004
CRP 16.0 ± 13.2 20.0 ± 4.4‘ 0.002
IL6 11.39 ± 2.78 14.22 ± 2.51 0.002
O2 saturation on room air 96.55 ± 1.09 95.25 ± 1.21 0.001
Platelet 154.05 ± 18.6 133.7 ± 25.6 0.007
Time of switch to oral 3.45 ± 0.48 4.27 ± 0.81 0.001
Table 1 Comparison between studied groups at time of admission.
On admission
Dexamethasone group Placebo group P-value
Age 34.15 ± 7.37 31.40 ± 6.67 0.22
ALT 174.25 ± 48.37 154.2 ± 47.32 0.19
AST 121.0 ± 36.83 129.10 ± 31.74 0.85
CRP 25.05 ± 5.04 25.05 ± 5.05 1.0
IL6 18.57 ± 4.09 18.79 ± 3.07 0.85
O2 saturation on room air 91.85 ± 1.98 91.9 ± 1.99 0.93
Po2 on room air 61.05 ± 1.61 60.85 ± 1.72 0.71
PH 7.4 ± 0.05 7.38 ± 0.05 0.42
Plt 102.95 ± 31.31 103.45 ± 33.16 0.96
WBCs 5.8 ± 1.5 6.34 ± 1.24 0.23
Serum creatinine 89.55 ± 13.02 88.55 ± 13.23 0.81
Dexamethasone as adjunctive therapy for treatment of varicella pneumonia 1120 male patients. Ten (50%) of 20 patients in the dexametha-
sone group were current smokers at the time of admission
compared with nine (45%) of 20 patients in the placebo group.
Each group involved three patients (15%) had history of
underlying pulmonary disease (bronchial asthma). Known
cases of diabetes mellitus were three (15%) of 20 patients in
the dexamethasone group and two (10%) of 20 patients in
the placebo group. These diabetic patients in both groups
needed additional glucose lowering treatment during their hos-
pital stay.
The mean length of hospital stay in the dexamethasone
group was 6.5 days (±0.76) compared with 7.15 days
(±0.98) in the placebo group. Length of hospital stay differed
signiﬁcantly between groups (P-value = 0.02, Table 3). Allpatients were treated with intravenous acyclovir in proper dose
within one hour of admission to hospital. The mean time of
switching to oral acyclovir was 3.45 days in the dexamethasone
group and 4.27 days in the placebo group. The mean time of
switching to oral acyclovir was signiﬁcantly lower in dexa-
methasone group than in placebo group (P-value = 0.001,
Table 2).
At time of admission, there were no signiﬁcant differences
between the dexamethasone group and the placebo group as
regard oxygen saturation, arterial blood gases, platelets, white
blood cells, C-reactive protein, interleukin-6 concentrations,
serum creatinine and liver enzymes (Table 1). After 4 days of
admission, we observed a signiﬁcant improvement in oxygen
saturation and platelets in the dexamethasone group than we
12 M.A. Saraya, A.E.-A.I. Amaldid in the placebo group. Also, we noted a signiﬁcant decline in
C-reactive protein, interleukin-6 concentrations and liver en-
zymes (ALT & AST) in the dexamethasone group than we
did in the placebo group (Table 2).
At time of discharge, the same signiﬁcant declines in C-
reactive protein and interleukin-6 concentrations were ob-
served between two groups (Table 3). There was no signiﬁcant
difference regarding PaCO2 in both groups on the day of pre-
sentation, after 4 days of admission and on the day of dis-
charge from the hospital.
Discussion
Due to the systemic nature of the disease, varicella can involve
any organ of the body; as it was observed, males, smokers,
pregnancy and immunodeﬁcient individuals are associated
with higher complication rates [14]. Varicella pneumonia is
the most common complication in adults and its incidence
has been reported variably. Gregorakos et al. [15] reported
the incidence of varicella pneumonia as high as 50%. As it
was observed in this study, most reported cases of varicella
pneumonia in both groups have occurred in cigarette smokers.
Cigarette smoking is a major risk factor for the development of
Varicella pneumonia in adults because of underlying damage
to alveolar macrophages [16]. It was also noted that all the pa-
tients were male, an observation that was also made in similar
studies. This may be explained by the fact that smoking is
more common in males [17].
In this study, we observed that all patients in both groups
are associated with mild hepatitis, as reported by others
[15,16]. The haematological changes in chickenpox are not
uncommon, particularly thrombocytopenia. In our study, we
observed that thrombocytopenia is a constant feature in all pa-
tients of both groups which is consistent with Ali et al. [18]. In
the ﬁrst 4 days after admission, we noted that the dexametha-
sone group showed a much more rapid improvement in liver
enzymes and platelet count than control group.
In our trial, we noted an overall reduction in mean length of
hospital stay of 1 day in patients with varicella pneumonia
who were given intravenous dexamethasone compared with
who were given intravenous placebo. Also, we noted the mean
time of switching to oral treatment was signiﬁcantly lower in
dexamethasone group than in placebo group. These ﬁndings
support our hypothesis that early administration of dexameth-
asone changes the immune response and thereby reduces
length of hospital stay in patients with varicella pneumonia.
This modulation is shown in the accelerated return to normal
concentrations of C-reactive protein and interleukin-6 that we
noted more in the dexamethasone group especially in the ﬁrst
4 days after admission.
In Varicella pneumonia, locally produced pulmonary cyto-
kines are needed to control and eliminate the primary infec-
tion. However, organ dysfunction can result from a systemic
inﬂammatory response [19]. Therefore, a balanced cytokine re-
sponse needs to be sufﬁcient to control the local infection but
not be excessive, to prevent systemic effect. So, adding of cor-
ticosteroids would reduce the systemic complications of the
inﬂammatory response without affecting the resolution of local
inﬂammation [12]. In this study, which is almost consistent
with the above reports, the improvement of hepatitis, throm-
bocytopenia and decline of CRP & IL-6 that we noted morein the dexamethasone group especially in the ﬁrst 4 days after
admission support our hypothesis that the use of corticoste-
roids as adjunctive therapy in combination with acyclovir for
the treatment of varicella pneumonia would reduce the sys-
temic inﬂammatory response with subsequent of improvement
organs dysfunction.Conclusion
Our study shows that a 4-days course of 5 mg dexamethasone
reduces length of hospital stay in patients admitted for vari-
cella pneumonia. The faster decline in concentrations of C-
reactive protein (CRP) and interleukin-6 (IL-6) that we noted
in patients given dexamethasone compared with controls sup-
port the notion that dexamethasone reduces the systemic
inﬂammatory response. The beneﬁts of corticosteroids should
be weight against the potential side effects of these drugs, such
as super-infection, hyperglycemia and gastric disturbance.References
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